Role of PQBP1 in Pathogen Recognition-Impact on Innate Immunity.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI

Immunity, Innate*; Humans ; Animals ; DNA-Binding Proteins/genetics ; DNA-Binding Proteins/metabolism ; DNA-Binding Proteins/immunology ; Protein Binding ; Carrier Proteins/metabolism ; Carrier Proteins/immunology ; Carrier Proteins/genetics ; HIV-1/immunology ; HIV-1/genetics ; Host-Pathogen Interactions/immunology

The intrinsically disordered polyglutamine-binding protein 1 (PQBP1) has been linked to various cellular processes including transcription, alternative splicing, translation and innate immunity. Mutations in PQBP1 are causative for neurodevelopmental conditions collectively termed as the Renpenning syndrome spectrum. Intriguingly, cells of Renpenning syndrome patients exhibit a reduced innate immune response against human immunodeficiency virus 1 (HIV-1). PQBP1 is responsible for the initiation of a two-step recognition process of HIV-1 reverse-transcribed DNA products, ensuring a type 1 interferon response. Recent investigations revealed that PQBP1 also binds to the p17 protein of avian reovirus (ARV) and is affected by the ORF52 of Kaposi's sarcoma-associated herpesvirus (KSHV), possibly also playing a role in the innate immune response towards these RNA- and DNA-viruses. Moreover, PQBP1-mediated microglia activation in the context of tauopathies has been reported, highlighting the role of PQBP1 in sensing exogenous pathogenic species and innate immune response in the central nervous system. Its unstructured nature, the promiscuous binding of various proteins and its presence in various tissues indicate the versatile roles of PQBP1 in cellular regulation. Here, we systematically review the available data on the structure of PQBP1 and its cellular functions and interactome, as well as possible implications for innate immune responses and neurodegenerative disorders.

Curr Opin Immunol. 2021 Oct;72:158-166. (PMID: 34062364)
Nat Commun. 2021 Nov 15;12(1):6565. (PMID: 34782623)
Signal Transduct Target Ther. 2021 Aug 4;6(1):291. (PMID: 34344870)
ACS Chem Neurosci. 2024 Aug 7;15(15):2665-2694. (PMID: 38996083)
Annu Rev Pathol. 2019 Jan 24;14:1-27. (PMID: 30089230)
Int J Mol Sci. 2022 Jun 02;23(11):. (PMID: 35682906)
Elife. 2012 Dec 18;1:e00047. (PMID: 23251783)
Genes Brain Behav. 2018 Feb;17(2):118-125. (PMID: 28782255)
Front Aging Neurosci. 2023 Sep 07;15:1245904. (PMID: 37744399)
Sci Rep. 2015 Sep 15;5:13895. (PMID: 26370624)
Vet Microbiol. 2022 Jan;264:109294. (PMID: 34847454)
J Biol Chem. 2003 Oct 17;278(42):41452-61. (PMID: 12888569)
Cell. 2015 Jun 4;161(6):1293-1305. (PMID: 26046437)
Avian Dis. 1973 Apr-Jun;17(2):415-24. (PMID: 4351420)
Mol Syndromol. 2020 Jul;11(3):157-161. (PMID: 32903913)
Mol Psychiatry. 2024 Feb;29(2):287-296. (PMID: 38030819)
Semin Cell Dev Biol. 2018 May;77:51-62. (PMID: 28969983)
Biochem Biophys Res Commun. 2005 Oct 21;336(2):709-15. (PMID: 16143310)
J Biol Chem. 1999 Dec 17;274(51):36513-9. (PMID: 10593949)
Eur J Neurosci. 2005 Sep;22(6):1277-86. (PMID: 16190883)
Nat Rev Immunol. 2016 Sep;16(9):566-80. (PMID: 27455396)
Alzheimers Dement (N Y). 2018 Sep 06;4:575-590. (PMID: 30406177)
Curr HIV/AIDS Rep. 2015 Mar;12(1):16-24. (PMID: 25604237)
Cell Syst. 2016 Mar 23;2(3):196-208. (PMID: 27135365)
PLoS One. 2009;4(1):e4104. (PMID: 19119319)
Ann Transl Med. 2018 May;6(10):175. (PMID: 29951497)
Ageing Res Rev. 2021 May;67:101272. (PMID: 33571704)
FEBS Lett. 2002 Feb 20;513(1):30-7. (PMID: 11911877)
Nat Rev Mol Cell Biol. 2017 May;18(5):285-298. (PMID: 28225081)
J Virol. 1976 Sep;19(3):968-76. (PMID: 987252)
Med Microbiol Immunol. 2019 Aug;208(3-4):495-512. (PMID: 30805724)
Development. 2014 Oct;141(19):3740-51. (PMID: 25209246)
Glia. 2017 Sep;65(9):1397-1406. (PMID: 28519900)
Mol Immunol. 2018 Jul;99:182-190. (PMID: 29807326)
Hum Mol Genet. 2011 Dec 15;20(24):4916-31. (PMID: 21933836)
Genes Dev. 2000 Jun 15;14(12):1415-29. (PMID: 10859161)
J Gen Virol. 2015 Jun;96(Pt 6):1436-1445. (PMID: 26068188)
J Med Genet. 2006 Jun;43(6):e30. (PMID: 16740914)
Proteomics. 2004 Mar;4(3):643-55. (PMID: 14997488)
Cell Death Differ. 2022 Jan;29(1):192-205. (PMID: 34385679)
Nat Commun. 2014 Apr 30;5:3822. (PMID: 24781215)
Genes Dev. 2013 Mar 15;27(6):615-26. (PMID: 23512658)
Hippocampus. 2013 Feb;23(2):129-38. (PMID: 22996287)
Nat Struct Biol. 2000 May;7(5):375-9. (PMID: 10802733)
Nat Cell Biol. 2017 Apr;19(4):362-374. (PMID: 28346439)
Biochem Biophys Res Commun. 2000 Jul 5;273(2):592-5. (PMID: 10873650)
Science. 2013 Aug 23;341(6148):903-6. (PMID: 23929945)
EMBO J. 2004 Jun 16;23(12):2381-91. (PMID: 15175653)
J Mol Biol. 1999 Oct 22;293(2):321-31. (PMID: 10550212)
Nature. 2020 Jul;583(7817):590-595. (PMID: 32669714)
Mol Cell. 2021 Apr 1;81(7):1425-1438.e10. (PMID: 33662272)
J Mol Biol. 2024 Feb 15;436(4):168409. (PMID: 38128824)
J Mol Biol. 2002 Oct 25;323(3):573-84. (PMID: 12381310)
J Neuroinflammation. 2020 Oct 13;17(1):298. (PMID: 33050925)
Biochem Biophys Res Commun. 2020 Mar 19;523(4):894-899. (PMID: 31959475)
Mol Cell. 2022 Aug 4;82(15):2871-2884.e6. (PMID: 35809572)
Biochem Biophys Res Commun. 1998 Dec 9;253(1):16-20. (PMID: 9875212)
Proteins. 2001 Jan 1;42(1):38-48. (PMID: 11093259)
Nucleic Acids Res. 1999 May 1;27(9):1957-65. (PMID: 10198427)
Clin Genet. 2011 Mar;79(3):225-35. (PMID: 20950397)
Genome Biol. 2024 Jan 15;25(1):17. (PMID: 38225666)
Science. 2019 Mar 8;363(6431):. (PMID: 30846571)
Nat Rev Immunol. 2014 Jul;14(7):463-77. (PMID: 24962261)
J Biol Chem. 2005 Nov 18;280(46):38862-9. (PMID: 16162498)
Mol Psychiatry. 2015 Apr;20(4):459-71. (PMID: 25070536)
Neuron. 2002 May 30;34(5):701-13. (PMID: 12062018)
Science. 2013 Feb 15;339(6121):786-91. (PMID: 23258413)
Nat Cell Biol. 2017 Sep;19(9):1061-1070. (PMID: 28759028)
Front Immunol. 2020 Aug 04;11:1473. (PMID: 32849504)
Transl Neurodegener. 2016 Apr 05;5:7. (PMID: 27054030)
Immunity. 2013 Dec 12;39(6):1019-31. (PMID: 24332030)
J Neurosci. 2010 Oct 20;30(42):14091-101. (PMID: 20962230)
Biophys J. 2012 Apr 4;102(7):1608-16. (PMID: 22500761)
Mol Neurodegener. 2023 Nov 8;18(1):79. (PMID: 37941028)
Nat Rev Immunol. 2011 Feb;11(2):143-54. (PMID: 21267015)
Cell. 2006 Aug 11;126(3):543-58. (PMID: 16901787)
Exp Mol Med. 2006 Aug 31;38(4):333-47. (PMID: 16953112)
Viruses. 2022 Apr 25;14(5):. (PMID: 35632635)
Nat Genet. 2003 Dec;35(4):313-5. (PMID: 14634649)
J Cell Biol. 2020 Jan 6;219(1):. (PMID: 31874114)
J Biol Chem. 2020 Mar 27;295(13):4093-4100. (PMID: 32041777)
Arch Biochem Biophys. 2008 May 15;473(2):231-6. (PMID: 18410742)
Mol Cell. 2021 Jul 1;81(13):2823-2837.e9. (PMID: 34015248)
Science. 2018 Aug 17;361(6403):704-709. (PMID: 29976794)
Nat Rev Endocrinol. 2018 Oct;14(10):576-590. (PMID: 30046148)
Biochim Biophys Acta. 2010 Jul;1804(7):1500-7. (PMID: 20307692)
Circ Genom Precis Med. 2019 Jun;12(6):e002390. (PMID: 31059280)
Pathogens. 2022 Jul 19;11(7):. (PMID: 35890053)
Nat Commun. 2016 Nov 10;7:13348. (PMID: 27830700)
Biochim Biophys Acta. 2009 Jun;1794(6):936-43. (PMID: 19303059)
Nature. 2023 Aug;620(7973):374-380. (PMID: 37532932)
Virus Res. 2023 Jul 15;332:199119. (PMID: 37201645)
Cell Rep. 2013 Sep 12;4(5):879-89. (PMID: 23994472)
Virus Res. 2021 May;297:198346. (PMID: 33741393)
Hum Mol Genet. 1999 Jun;8(6):977-87. (PMID: 10332029)
Mol Cell. 2017 Aug 3;67(3):387-399.e5. (PMID: 28712728)
Am J Med Genet A. 2005 May 1;134(4):415-21. (PMID: 15782410)
Biochemistry. 2002 May 28;41(21):6573-82. (PMID: 12022860)

SPP1923 project KO4573/1-2 Deutsche Forschungsgemeinschaft

Keywords: PQBP1; Renpenning syndrome spectrum; innate immunity; neurodegeneration

0 (PQBP1 protein, human)
0 (DNA-Binding Proteins)
0 (Carrier Proteins)

Date Created: 20240829 Date Completed: 20240829 Latest Revision: 20240903

20240903

PMC11360342

10.3390/v16081340

39205314